The 6th WSPH Task Force on Hemodynamic Definitions and Clinical Classification recently proposed reducing the diagnostic mPAP threshold for pulmonary hypertension.
PAH associated with CHD is linked to significant reductions in survival and quality of life, especially for patients progressing to Eisenmenger syndrome.
Although pulmonary hypertension as a result of interstitial lung disease is linked to significant morbidity and mortality, there is no consensus regarding screening or management of the disease.
Emerging evidence suggests that the extrapulmonary effects of pulmonary arterial hypertension may manifest in the form of vascular dysfunction in systemic circulation, metabolic/endocrine dysfunction, and skeletal and respiratory muscle dysfunction.
Researchers sought to determine the efficacy and safety of percutaneous transluminal pulmonary angioplasty for Takayasu arteritis-associated pulmonary HTN.
Among patients with pulmonary arterial hypertension, what is the relationship between Hispanic ethnicity, social determinants of health, and clinical outcomes?
How effective are the 3 most commonly used pulmonary arterial hypertension risk assessment tools — REVEAL, COMPERA, and FPHR — in predicting mortality risk?
